JWJens Waschke

Jens Waschke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jens Waschke has a total of 398 co-authors. Here are the top co-authors by number of shared publications:

  • Volker Spindler

    Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg- Eppendorf, Hamburg, Germany

    35 shared publications
  • Daniela Kugelmann

    Chair of Vegetative Anatomy, Faculty of Medicine, Institute of Anatomy, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany

    18 shared publications
  • Franziska Vielmuth

    Institute of Anatomy, Faculty of Medicine, Ludwig-Maximilians-Universität LMU Munich 1 Chair of Vegetative Anatomy 80336 Munich

    15 shared publications
  • Franziska Vielmuth

    Institute of Anatomy, Faculty of Medicine, Ludwig-Maximilians-Universität München , Munich

    15 shared publications
  • Michael Hertl

    Department of Dermatology and Allergology, Philipps University, Marburg, Germany

    13 shared publications
  • Mariya Y. Radeva

    Chair of Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, LMU Munich, Munich, Germany

    12 shared publications

Latest Publications

  • Preservation of desmosome health: a new treatment paradigm?

    by Jens Waschke

    Pemphigus is a model disease for desmosome dysfunction caused by autoantibodies. We propose that for therapy of pemphigus and other diseases where desmosome function is compromised, preservation of desmosome health may become a new paradigm.

  • Open Access

    Erlotinib impairs epidermal tight junction and barrier integrity by inhibiting EGFR and Src and affects maturation of cell-cell junctions in human and mouse keratinocytes.

    by Keisuke Imafuku, Alexander Garcia-Ponce, Jens Waschke

    Erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, is widely used in cancer therapy but frequently causes cutaneous adverse effects that suggest impairment of the epidermal barrier. To better understand the underlying mechanisms, we examined how erlotinib affects barrier integrity, with a focus on tight junctions (TJs) and their relation with the actin cytoskeleton. Using human and mouse ex vivo epidermis as well as cultured keratinocytes, we assessed junctional assembly and stability under pharmacological inhibition of EGFR and Src. Erlotinib treatment disrupted the epithelial barrier, as demonstrated by enhanced biotin tracer penetration and a marked reduction in transepithelial electrical resistance. In line with functional impairment, erlotinib reduced EGFR and Src activity disturbing maturation of junctions, as evidenced by discontinuous claudin-1 and ZO-1 localization. Furthermore, erlotinib induced a loss of the apically localized tension-sensitive conformation of α-catenin in the stratum granulosum and in cultured keratinocytes. This was accompanied by disorganization of cortical actin and increased presence of stress fibers, in parallel with elevated activation of RhoA and phosphorylation of MLC2. Inhibition of Src with PP2 led to similar effects on barrier integrity. However, this detrimental outcome could be rescued by EGF treatment. Together, these findings indicate that erlotinib impairs epidermal barrier function by affecting junctional maturation via disrupted α-catenin membrane distribution, and ultimately, TJ stability involving intracellular contraction and tension. Thus, strategies focused on targeting tension‑related mechanisms downstream of EGFR/Src might help prevent or alleviate the cutaneous toxicities associated with EGFR inhibitory therapies.


  • Open Access

    STED/AFM as a tool to investigate mechanical and adhesive properties of migrating keratinocytes

    by Mariya Y. Radeva, Jens Waschke, Michael Fuchs

    E-cadherin is a key component of adherens junctions which maintains epithelial integrity. In keratinocytes, wound healing requires dynamic modulation of adhesion and cytoskeletal organization. Using a wound healing assay combined with stimulated emission depletion/atomic force microscopy (STED/AFM), we analysed E-cadherin binding during murine keratinocyte migration. Wound closure occurred within 6 h and was accompanied by E-cadherin accumulation at the leading edge. Transient expression of E-Cadherin-SNAP enabled investigation of E-cadherin interactions. Inhibition of actin polymerization abolished E-cadherin binding and reduced cellular stiffness. Imaging of SiR-actin-labeled cells enabled simultaneous visualization of migration and measurement of binding and mechanical properties. E-cadherin retained functional binding properties during migration. These findings establish STED/AFM as a powerful method to investigate single-molecule binding properties in migrating cells.


  • Open Access

    Plakoglobin phosphorylation at serine 665 is capable of stabilizing cadherin-mediated adhesion in keratinocytes

    by Franziska Vielmuth, Anna M. Sigmund, Desalegn T. Egu, Matthias Hiermaier, Letyfee S. Steinert, Sina Moztarzadeh, Mariia Klimkina, Margarethe E.C. Schikora, Paulina M. Rion, Thomas Schmitt, et al.

    In pemphigus, autoantibodies against the desmosomal cadherins desmoglein (DSG) DSG1 and DSG3 cause intraepidermal blistering. Recently, we found that increasing cAMP with the phosphodiesterase-4 inhibitor apremilast stabilizes keratinocyte cohesion in pemphigus. This effect is paralleled by phosphorylation of the desmosomal plaque protein plakoglobin (PG) at serine 665 (S665). Here, we investigated the relevance of PG phosphorylation at S665 for stabilization of keratinocyte cohesion and further characterized the underlying mechanisms. Ultrastructural analysis of a recently established PG-S665 phospho-deficient mouse model (PG-S665A) showed diminished keratin insertion. Accordingly, the protective effect of apremilast against pemphigus autoantibody-induced skin blistering was diminished, and apremilast failed to restore alterations of the keratin cytoskeleton in PG-S665A mice. Keratinocytes derived from PG-S665A mice revealed a disorganized keratin cytoskeleton and reduced single-molecule binding strength of DSG3. In line with this, in ex vivo human skin, increased cAMP augmented keratin insertion into desmosomal plaques. Additionally, PG phosphorylated at S665 colocalized with desmoplakin and keratin filaments anchoring to desmosomes and increased cAMP-accelerated assembly of desmosomes. Taken together, phosphorylation of PG at S665 was crucial for protective effects of apremilast in pemphigus and for maintenance of DSG3 binding and keratin filament anchorage to desmosomes.

  • Open Access

    Role of protein kinase C subtype-specific signalling in regulating adhesion in human keratinocytes and skin in pemphigus

    by Thomas Schmitt, Julia Haneberg, Desalegn Tadesse Egu, Carla Sebastià Morón, Enno Schmidt, Christoph Hudemann, Michael Hertl, Takashi Hashimoto, Jens Waschke

    Background: Autoantibodies in the blistering skin disease pemphigus primarily target desmosomal cadherins and cause loss of keratinocyte adhesion and epidermal blistering via signalling events. Pemphigus vulgaris (PV) is associated with autoantibodies (PV IgG) against desmoglein (Dsg)1 and Dsg3 and pemphigus foliaceus (PF) with antibodies against Dsg1 only. In previous studies, protein kinase C (PKC) inhibition was protective in murine but not in human epidermis. Objectives: To investigate the roles of PKC subtypes in in PV IgG-induced epidermal blistering in human skin. Methods: We applied an ex vivo human skin organ culture model, dispase-based dissociation assays, Western blot analysis and confocal and simulated emission depletion (STED) microscopy, to study the underlying mechanisms of pemphigus pathogenesis in vitro. Results: The inhibitor of atypical PKC (aPKC) isoforms CRT0066854 (CRT) completely abolished acantholysis, whereas the conventional PKC (cPKC) inhibitor Gö6976 (Gö) did not. In cultured keratinocytes, both CRT and Gö effectively inhibited the loss of cell adhesion, keratin filament retraction and Dsg3 depletion in response to PV IgG, as well the pathogenic Dsg3-specific IgGs AK23 and 2G4. In contrast, reduced cell adhesion and keratin filament retraction in response to PKC activation by phorbol-12-myristate-13-acetate and PF IgG was blocked by the inhibition of cPKC but not of aPKC. Mechanistically, cPKC and aPKC were both required for PV IgG-induced translocation of PKC towards peripheral keratin filaments and conformational changes in desmoplakin. Conclusions: These findings show that aPKC is critical for the blistering seen in human epidermis in PV and is dependent on the autoantibody profile.


  • Open Access

    Apremilast improves cardiomyocyte cohesion and arrhythmia in different models for arrhythmogenic cardiomyopathy

    by Konstanze Stangner, Orsela Dervishi, Janina Kuhnert, Carl Wendt, Soumyata Pathak, Maria Shoykhet, Silvana Olivares-Florez, Sina Moztarzadeh, Jens Opsteen, Ni Luh Cathrin Suniasih Wohlfarth, et al.

    Background: Arrhythmogenic cardiomyopathy (ACM) is a genetically inherited desmosome heart disease leading to life-threatening arrhythmias and sudden cardiac death. Currently, ACM treatment paradigms are merely symptom targeting. Recently, apremilast was shown to stabilize keratinocyte adhesion in the desmosomal disease pemphigus vulgaris. Therefore, this study investigated whether apremilast can be a therapeutic option for ACM. Methods: Human induced pluripotent stem cells from a healthy control (hiPSC) and an ACM index patient (ACM-hiPSC) carrying a heterozygous desmoplakin ( DSP ) gene mutation (c.2854G > T, p.Glu952Ter), confirmed by whole exome sequencing (WES), were established. Cyclic-AMP ELISA, dissociation assay, immunostaining, and Western blotting analyses were performed in human iPSC-derived cardiomyocytes (hiPSC-CMs), murine HL-1 cardiomyocytes, and cardiac slices derived from wild-type (WT) mice, plakoglobin (PG, Jup ) knockout ( Jup −/− ) (murine ACM model) or PG Serine 665 phosphodeficient (JUP-S665A) mice. Microelectrode array (MEA) analyses in ventricular cardiac slices and Langendorff heart perfusion were performed to analyze heart rate variability and arrhythmia. Results: ACM-hiPSC derived cardiomyocytes (ACM-hiPSC-CMs) revealed a significant loss of cohesion, which was rescued by apremilast. Further, treatment with apremilast strengthened basal cardiomyocyte cohesion in HL-1 cells and WT murine cardiac slices, paralleled by phosphorylation of PG at Serine 665 in human and murine models. In HL-1 cells, apremilast in addition activated ERK1/2, inhibition of which abolished apremilast-enhanced cardiomyocyte cohesion. Further, dissociation assays in slice cultures from JUP-S665A and Jup −/− mice revealed that PG is crucial for apremilast-enhanced cardiomyocyte cohesion. In parallel to enhanced cell adhesion, MEA and Langendorff measurements from WT and Jup −/− mice demonstrated decreased heart rate variability and arrhythmia after apremilast treatment. Conclusions: Apremilast improves loss of cardiomyocyte cohesion, enhances localization of DSG2, and reduces arrhythmia in human and/or murine models of ACM ex vivo and in vitro, providing a novel treatment strategy for ACM by preserving desmosome function.


  • Open Access

    Autoantibodies in patients with arrhythmogenic cardiomyopathy activate GSK-3β resulting in a loss of cardiomyocyte cohesion

    by Soumyata Pathak, Konstanze Stangner, Ellen Kempf, Sina Moztarzadeh, Matthias Hiermaier, Marlene Rauschmayer, Tatjana Williams, Andreas Stengl, Brenda Gerull, Ruth Biller, et al.

    Arrhythmogenic cardiomyopathy (ACM) is an inherited cardiac desmosome disease, as more than 50% of affected patients carry pathogenic variants in desmosome protein-coding genes., In this study, we focused on the role and mechanisms of pathogenic and non-pathogenic autoantibodies against intercalated disc (ICD) proteins such as desmoglein2 (DSG2) in ACM patients, healthy relatives and murine ACM models. IgG fractions from ACM patients and healthy relatives, but not murine ACM model-derived or healthy control IgGs, revealed positive ICD staining. Antibodies reducing the loss of cardiomyocyte cohesion were found in three out of five ACM patients. Pathogenic autoantibodies, bound to DSG2 in hiPSC-CMs, cleaved DSG2 and reduced DSG2 interaction at the molecular level. We investigated GSK-3β contribution to the loss of cardiomyocyte cohesion and observed that GSK-3β reduced baseline cardiomyocyte cohesion in cultured cardiomyocytes and cardiac slices. Pathogenic ACM-IgGs activated GSK-3β upstream of p38MAPK, leading to phosphorylation and junctional loss of β-catenin. GSK-3β inhibition rescued the loss of cell cohesion induced by ACM-IgGs in ACM hiPSC-CMs. Pathogenic autoantibodies targeting DSG2 are present in ACM patients and impair cardiomyocyte cohesion in a GSK-3β-dependent manner. In contrast, autoantibodies are absent in murine ACM models and are non-pathogenic in some patients, healthy relatives.

  • Open Access

    The Multikinase Inhibitor Midostaurin Mitigates Loss of Intercellular Adhesion and Skin Blistering in Pemphigus Vulgaris

    by Matthias Hiermaier, Desalegn Tadesse Egu, Anna Magdalena Sigmund, Nancy Ernst, Ralf Joachim Ludwig, Michael Hertl, Kamran Ghoreschi, Enno Schmidt, Takashi Hashimoto, Jens Waschke


  • Direct inhibition precedes p38 mitogen activated protein kinase-mediated uncoupling in desmosomes to reduce desmoglein 3 adhesion by pemphigus autoantibodies

    by Michael Fuchs, Miriam Möchel, Mariya Y Radeva, Thomas Schmitt, Amir S Yazdi, Takashi Hashimoto, Jens Waschke

    Background: Pemphigus vulgaris (PV) is an autoimmune blistering skin disease caused by impaired desmosome adhesion. Altered signalling pathways and direct inhibition of desmoglein (Dsg) binding contribute to loss of cell adhesion, but the sequence of these events is still a matter of debate. Objectives: To characterize the early sequence of events following autoantibody binding to Dsg3 in the pathogenesis of pemphigus. Methods: We established stimulated emission depletion imaging in combination with atomic force microscopy single-molecule force measurements to elucidate the primary events following autoantibody binding. Therefore, we measured the Dsg3 binding properties on individual desmosomes and used Triton X-100 fractionation, Western blotting, immunofluorescence and keratinocyte dissociation assays. Results: We found that the primary loss of cell adhesion and Dsg3 binding occurs in human keratinocytes as soon as autoantibodies are detectable in desmosomes, which is as early as 5 min for the monoclonal anti-Dsg3 antibody AK23 and 15 min after the addition of PV IgG autoantibodies from patients. Activation of p38 mitogen-activated protein kinase (MAPK) – a central signalling mechanism in PV – was significant after 30 min but not detectable in desmosomes after 5 min of AK23 incubation. Nevertheless, p38 MAPK was required for the loss of cytoskeletal anchorage of Dsg3 molecules in desmosomes and inhibition of p38 MAPK-blunted loss of Dsg3 binding and cell adhesion. Conclusions: The results show that autoantibody-induced direct inhibition of Dsg3 binding precedes p38 MAPK-mediated cytoskeletal uncoupling at desmosomes. Thus, the signalling function of Dsg3 in activating p38 MAPK is triggered by the loss of transinteraction, which is the primary target point for therapeutic strategies to stabilize keratinocyte adhesion in PV.


  • Open Access

    Apremilast improves cardiomyocyte cohesion and arrhythmia in different models for arrhythmogenic cardiomyopathy

    by Konstanze Stangner, Orsela Dervishi, Janina Kuhnert, Carl Wendt, Soumyata Pathak, Maria Shoykhet, Silvana Olivares Florez, Sina Moztarzadeh, Jens Opsteen, Ni Luh Cathrin Suniasih Wohlfarth, et al.

    Background: Arrhythmogenic cardiomyopathy (ACM) is a genetically inherited desmosome heart disease leading to life-threatening arrhythmias and sudden cardiac death. Currently, ACM treatment paradigms are merely symptom targeting. Recently, apremilast was shown to stabilize keratinocyte adhesion in the desmosomal disease pemphigus vulgaris. Therefore, this study investigated whether apremilast can be a therapeutic option for ACM. Methods: Human induced pluripotent stem cells from a healthy control (hiPSC) and an ACM index patient (ACM-hiPSC) carrying a heterozygous desmoplakin ( DSP ) gene mutation (c.2854G>T, p.Glu952Ter), confirmed by whole exome sequencing (WES), were established. Cyclic-AMP ELISA, dissociation assay, immunostaining, and Western blotting analyses were performed in human iPSC-derived cardiomyocytes (hiPSC-CMs), murine HL-1 cardiomyocytes, and cardiac slices derived from wild-type (WT) mice, plakoglobin (PG, Jup ) knockout ( Jup -/- ) (murine ACM model) or PG Serine 665 phosphodeficient (JUP-S665A) mice. Microelectrode array (MEA) analyses in ventricular cardiac slices and Langendorff heart perfusion were performed to analyze heart rate variability and arrhythmia. Results: ACM-hiPSC derived cardiomyocytes (ACM-hiPSC-CMs) revealed a significant loss of cohesion, which was rescued by apremilast. Further, treatment with apremilast strengthened basal cardiomyocyte cohesion in HL-1 cells and WT murine cardiac slices, paralleled by phosphorylation of PG at Serine 665 in human and murine models. In HL-1 cells, apremilast in addition activated ERK1/2, inhibition of which abolished apremilast-enhanced cardiomyocyte cohesion. Further, dissociation assays in slice cultures from JUP-S665A and Jup -/- mice revealed that PG is crucial for apremilast-enhanced cardiomyocyte cohesion. In parallel to enhanced cell adhesion, MEA and Langendorff measurements from WT and Jup -/- mice demonstrated decreased heart rate variability and arrhythmia after apremilast treatment. Conclusions: Apremilast improves loss of cardiomyocyte cohesion, enhances localization of DSG2, and reduces arrhythmia in human and murine models of ACM ex vivo and in vitro , providing a novel treatment strategy for ACM by preserving desmosome function. Translational perspective: The current therapeutic options for patients with arrhythmogenic cardiomyopathy (ACM) include lifestyle changes, treatment with anti-arrhythmic drugs, catheter ablation, implantable cardiac defibrillators, and ultimately, heart transplantation for patients who are having therapy refractory arrhythmia or developed heart failure. However, lifestyle changes, such as restraining from physical endurance activities and β-blocker therapy, are most used in patients carrying genetic variants coding for proteins of the desmosomal complex. Recent advancements hint that strategies enhancing intracellular cAMP could be beneficial in treating desmosomal diseases and can be effective therapeutics, which would be highly relevant for ACM patients. In this study, we show that apremilast improves loss of cardiomyocyte cohesion, enhances localization of desmosomal proteins, and reduces arrhythmia in both human and murine models of ACM ex vivo and in vitro, providing a novel treatment strategy for ACM by preserving desmosome function.